We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Genetic Causes of Bowel Cancer Clarified

By LabMedica International staff writers
Posted on 14 Jul 2016
Colorectal cancer (CRC) displays a complex pattern of inheritance and it is postulated that much of the missing heritability of CRC is enshrined in high-impact rare alleles, which are mechanistically and clinically important.

A landmark study has given the most detailed picture yet of the genetics of bowel cancer, the UK's fourth most common cancer, and the genetic architecture of CRC susceptibility encompasses a broad spectrum of risk, from rare, highly penetrant germline mutations associated with well-characterized syndromes to common polymorphisms, each individually conferring small risk.

Scientists at the Institute of Cancer Research (London, UK) and their colleagues included in a study 1,028 unrelated patients (559 male) with CRC, aged ≤55 years at diagnosis (mean age 48.7 ± 6.0), who had at least one first-degree relative with CRC, ascertained between 2003 and 2011. More...
All the patients were UK residents and had self-reported European ancestry. Germline DNA was isolated from EDTA-venous bloods using standard methods and picogreen quantified. The controls comprised 1,644 healthy individuals from the UK and an additional 670 individuals, all who were sequenced.

A Covaris E Series instrument (Covaris Inc., Woburn, MA, USA) was used to fragment 1 μg of DNA from each individual. Illumina’s Truseq 62 Mb expanded exome enrichment kit was used to prepare indexed paired-end libraries, 2 × 100 bp sequencing was performed using the HiSeq2000 technology (Illumina, San Diego, CA, USA). The scientists also performed read mapping and variant analysis, sample-level quality control, ExomeArray concordance and other methodologies.

The investigators found that added together, all the discovered variants in the known bowel cancer genes accounted for less than a third of familial cases of bowel cancer, those occurring in people whose close relatives had already developed it. The rest of the familial cases must therefore be caused largely by minor DNA variations that in combination add up to increase risk, with environmental factors also contributing. For an individual person, the risk of developing bowel cancer comes from a mix of inherited risk through their genes and environmental risk, which is caused by non-genetic factors such as lifestyle. Around 12% of cases occur in people with a family history of bowel cancer, with inherited mutations in known cancer-causing genes such as Adenomatous Polyposis Coli (APC) and MutL Homolog 1(MLH1) often playing a major role.

Richard S.Houlston, MD, PhD, a Professor of Molecular and Population Genetics and senior author of study, said, “Our study is the largest ever conducted of the genetics of bowel cancer, and sets out a detailed map of the disease that could lead us to new ways of treating or preventing it. Each cancer gene that has been discovered, or common genetic variant that we will continue to uncover, provides us with new insights into the underlying biology of the disease, and increases our ability to assess people for their risk.” The study was published on June 22, 2016, in the journal Nature Communications.

Related Links:
Institute of Cancer Research
Covaris
Illumina

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.